Generic Medicine Info
Indications and Dosage
Bone marrow transplantation
Adult: 10 mcg/kg (110,000 IU/kg) daily by infusion over 4-6 hr beginning on the day after the procedure and continued for 30 days depending on the neutrophil count. Max: 10 mcg/kg (110,000 IU/kg) daily.

Ganciclovir-induced neutropenia
Adult: 5 mcg/kg (60,000 IU/kg) daily. After the 5th dose, adjust dose according to neutrophil count. Max: 10 mcg/kg (110,000 IU/kg) daily.

Chemotherapy-induced neutropenia
Adult: 5-10 mcg/kg (60,000-110,000 IU/kg) daily starting 24 hr after last dose of chemotherapy and continued for 7-10 days. Max: 10 mcg/kg (110,000 IU/kg) daily.
Reconstitute the lyophilised powder with 1 ml of sterile water for inj. Further dilute the reconstituted solution in 25, 50 or 100 ml infusion bags or bottles of either normal saline solution or 5% dextrose in water. Infusion admixture solution should contain a final concentration of not <7 mcg/ml. Do not dilute below recommended min concentration (7 mcg/ml) since molgramostim solution may be adsorbed onto glass and plastic materials.
Add 1 ml of diluent (bacteriostatic water for inj or sterile water for inj) to the vial. Do not dilute below recommended min concentration (7 mcg/ml) since molgramostim solution may be adsorbed onto glass and plastic materials.
Myeloid malignancies. Lactation.
Special Precautions
Patients with any pre-malignant or malignant myeloid condition, pre-existing pulmonary disease. Discontinue use in patients who develop signs of pulmonary infiltrates. Patients with fluid retention or heart failure. Regularly monitor CBC during therapy. Pregnancy.
Adverse Reactions
Fever and chills, nausea, dyspnoea, diarrhoea, rash, rigors, inj site reaction (SC admin), vomiting, fatigue, anorexia, bone and musculoskeletal pain, asthenia, transient hypotension, non-specific chest pain, stomatitis, headache, increased sweating, abdominal pain, pruritus, dizziness, peripheral oedema, paraesthesia and myalgia. Antibodies can develop.
Potentially Fatal: Anaphylactic reactions, pleural and pericardial effusion, cardiac arrhythmias.
Symptoms: Tachycardia, hypotension, flu-like syndrome. Treatment: Symptomatic.
Drug Interactions
May increase occurrence of bleomycin-induced pulmonary toxicity.
Potentially Fatal: Increased risk of myelosuppression when given simultaneously with myelosuppressive cytotoxic antineoplastics. Do not use within 24 hr of cytotoxic chemotherapy.
Description: Molgramostim is a granulocyte-macrophage colony-stimulating factor (GM-CSF) that influences the growth, differentiation and function of the granulocytes, macrophages and eosinophils. It helps in the separation of granulocyte and macrophage pathways and also enhances cell function.
Store at 2-8°C. Do not freeze. Protect from light.
MIMS Class
Haematopoietic Agents
Disclaimer: This information is independently developed by MIMS based on Molgramostim from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in